Zakharov V V
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(6):93-99. doi: 10.17116/jnevro202212206193.
To assess the degree of satisfaction of outpatient neurologists with the results of therapy with Logacer 4 ml/1000 mg IM once daily in patients with chronic cerebral ischemia (CCI) and moderate cognitive impairment (MCI) in routine clinical practice.
The study involved 7777 patients with chronic cerebral ischemia aged 55-75 years. All patients had moderate cognitive impairment according to the MMSE scale. The patients were prescribed injection therapy with Logacer 4 ml/1000 mg 1 r/day IM for 10 days. Patient satisfaction and adherence to therapy was assessed using the Likert scale.
At the indicated doses, Logacer caused a pronounced positive effect on the neurological status and cognitive functions of patients with CCI and MCI. 3733 (49%) patients rated their satisfaction with the therapy with Logacer 3323 (43%) as 5 points - 4 points. 3988 (52%) patients rated adherence to therapy with Logacer at 5 points, 3261 (43%) patients - at 4 points.
The drug Logacer is characterized by high effectiveness and good tolerability in patients with CCI.
